Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients

被引：0
|
作者：
Diana Carmona-Fernandes
Maria José Santos
Inês Pedro Perpétuo
João Eurico Fonseca
Helena Canhão
机构：
[1] Instituto de Medicina Molecular,Rheumatology Research Unit
[2] Faculdade de Medicina da Universidade de Lisboa,Rheumatology Department
[3] Edifício Egas Moniz,Rheumatology and Bone Metabolic Diseases Department
[4] Hospital Garcia de Orta,undefined
[5] Hospital de Santa Maria,undefined
来源：
Arthritis Research & Therapy | / 13卷
关键词：
sRANKL; osteoprotegerin; systemic lupus erythematosus; osteoclastogenesis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Soluble receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation
    Chun-Hsiung Chen
    Hung-An Chen
    Hsien-Tzung Liao
    Chin-Hsiu Liu
    Chang-Youh Tsai
    Chung-Tei Chou
    Clinical Rheumatology, 2010, 29 : 1155 - 1161
  • [42] Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease
    Kearns, Ann E.
    Khosla, Sundeep
    Kostenuik, Paul J.
    ENDOCRINE REVIEWS, 2008, 29 (02) : 155 - 192
  • [43] The role of osteoprotegerin and receptor activator of nuclear factor κB ligand in the pathogenesis and treatment of rheumatoid arthritis
    Hofbauer, LC
    Heufelder, AE
    ARTHRITIS AND RHEUMATISM, 2001, 44 (02): : 253 - 259
  • [44] Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
    Lorenz C. Hofbauer
    Armin E. Heufelder
    Journal of Molecular Medicine, 2001, 79 : 243 - 253
  • [45] Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
    Hofbauer, LC
    Heufelder, AE
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2001, 79 (5-6): : 243 - 253
  • [46] Expression of the receptor activator for nuclear factor-κB ligand and osteoprotegerin in chronic otitis media
    Kuczkowski, Jerzy
    Sakowicz-Burkiewicz, Monika
    Izycka-Swieszewska, Ewa
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2010, 31 (06) : 404 - 409
  • [47] The Effect of Osteoprotegerin (OPG)/Receptor Activator of Nuclear Factor-κB Ligand (RANKL)/Receptor Activator of Nuclear Factor-κB (RANK) on Aortic Valve Calcified
    Luo, Wei
    Wang, Jing
    Yang, Xia
    Li, Junshan
    Song, Yanqiu
    Cong, Hongliang
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2024, 54 (05): : 633 - 642
  • [48] Protective Effect of Metformin on Periapical Lesions in Rats by Decreasing the Ratio of Receptor Activator of Nuclear Factor Kappa B Ligand/Osteoprotegerin
    Liu, Lingshuang
    Zhang, Chi
    Hu, Yajing
    Peng, Bin
    JOURNAL OF ENDODONTICS, 2012, 38 (07) : 943 - 947
  • [49] Relationship of serum osteoprotegerin (OPG), receptor activator of nuclear factor kappa-B ligand (RANKL), and 2-year change in bone mineral density, (BMD) in systemic lupus erythematosus (SLE).
    Lee, C
    Almagor, O
    Rhew, EY
    Eksarko, P
    McKinney, K
    Chadha, AB
    Dunlop, DD
    Spies, S
    Pope, RM
    Ramsey-Goldman, R
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S305 - S305
  • [50] The Relationship Between Fibroblast Growth Factor 23, Osteoprotegerin, Receptor Activator of Nuclear Factor κB Ligand and Osteoporosis in Patients with Prolactinoma
    Arsian, Muyesser Sayki
    Sahin, Mustafa
    Tutal, Esra
    Karakose, Melia
    Topaloglu, Oya
    Ucan, Bekir
    Demirci, Taner
    Caliskan, Mustafa
    Sahingoz, Seyda
    Cakal, Erman
    Ozbek, Mustafa
    Delibasi, Tuncay
    ENDOCRINE REVIEWS, 2014, 35 (03)
12345